Patent · US Active

Humanized anti-CD19 antibodies

US8883992B2 · kind B2 · utility

3Cited by
20References
9Claims
0Family size

Assignee

Inventors

Key dates

Filing dateOct 26, 2012
Grant dateNov 11, 2014
Priority date
Expiry dateOct 26, 2032

Classification

  • Technology area (CPC Y)Emerging Cross-Sectional Technologies
  • CPC primaryY02A50/30
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

Isolated nucleic acids encoding anti-CD19 mouse monoclonal antibodies are described herein. Also described are expression vectors, host cells and a method of producing anti-CD19 antibodies.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.